What Relaquine Treats: Main Uses and Benefits

Relaquine (Acepromazine maleate) is commonly used for its tranquilizing and sedative properties in veterinary medicine to address pronounced symptoms of acute behavioral agitation, restlessness, and resistance to handling. The primary therapeutic domains addressed include supporting the management of acute behavioral tension, facilitating pre-anesthesia, and providing symptomatic relief for specific conditions.

This approach generally supports a state of controlled calmness and sedation, which can assist with managing physical resistance in clinical settings involving procedures such as examinations or diagnostic imaging, where patient struggle may interfere with functional stability. The medication is commonly applied as a premedication to mitigate pre-operative anxiety and is relevant for managing symptoms of distress during stressful events like transportation. Furthermore, it is commonly used to help manage symptoms related to stress, such as nausea and vomiting associated with travel, and is considered relevant in certain circulatory conditions where it may assist with contributing to easing the overall symptom load.

---

Quick Fact: Relief for Acute Behavioral and Procedural Stress The primary use of Relaquine is to ease symptoms of situational anxiety and physical resistance, relevant for managing symptoms that interfere with essential veterinary care.

Regulatory References

1. FDA-approved label for Acepromazine Maleate Injection

Relaquine is approved for use exclusively in horses, dogs, and cats. Eligibility for this medicine is strictly defined by regulatory authorities based on species, physiological state, and existing medical conditions.

The medicine is contraindicated and must not be used in animals exhibiting severe medical conditions. These absolute exclusions include animals suffering from post-traumatic shock, hypovolemia, severe heart failure, or epilepsy (including a history of convulsions). Use is also prohibited in animals with severe anaemia, hypothermia, or known hypersensitivity to the active ingredient. Additionally, use is forbidden in animals recently exposed to organophosphate compounds.

Specific populations require conditional use or are formally not recommended. The use of Relaquine is contraindicated in neonates and generally restricted in young animals. Furthermore, the label states the medicine is contraindicated in pregnant or lactating mares. Caution and dose reduction are required for animals with pre-existing hepatic or cardiac disease, as well as for generally debilitated or hypotensive animals. The medicine must not be used in horses intended for human consumption.

Interactions with other medicines and products

The official regulatory profile for Acepromazine maleate (Relaquine) establishes specific constraints involving synergistic effects on the central and cardiovascular systems, alongside several formal prohibitions.

Formally Contraindicated Combinations

Regulatory documents strictly prohibit the co-administration of certain substances due to the risk of enhanced adverse outcomes. Co-use with Organophosphorus Compounds, which includes various ectoparasiticides and vermifuges, is forbidden because of the potential for potentiated toxicity. Similarly, combining Relaquine with Procaine Hydrochloride is formally contraindicated, as the activity of Procaine may be enhanced. Additionally, Epinephrine must not be used to treat acute hypotension that results from an Acepromazine overdosage, as this interaction can paradoxically cause a further, severe decrease in systemic blood pressure.

Pharmacodynamic and Disposition Interactions

Acepromazine is additive to the actions of all centrally depressant drugs. This potentiation extends to General Anesthetics, often requiring a formal reduced dosage requirement for the anesthetic agent when co-administered. The effects of Hypotensive Agents are also potentiated. A pharmacokinetic consideration is noted for oral formulations: Antacids may decrease the gastrointestinal absorption of the active ingredient. Finally, due to the substance being detoxified in the liver, regulatory authorities specify a caution for its use in individuals with a known history of hepatic dysfunction, indicating a risk of altered clearance.

Relaquine (Acepromazine maleate) exerts its physiological effects through a multi-receptor profile of antagonism, which initiates distinct and predictable cascades in both the central and peripheral nervous systems. The observed physiological changes are achieved by blocking specific neurotransmitter and humoral signaling pathways.

This mechanism involves the blockade of postsynaptic D2 dopamine receptors in brain regions that regulate emotion and spontaneous activity, such as the limbic system. By functionally inhibiting dopaminergic activity, the drug reduces spontaneous neurological signals, which results in marked central nervous system (CNS) depression and a state of reduced behavioral responsiveness.

In the periphery, the drug acts on vascular smooth muscle by blocking Alpha1 (alpha1) adrenergic receptors. This action prevents the natural binding of norepinephrine, thereby inhibiting the muscular constriction of blood vessels, and causes systemic vasodilation, resulting in hypotension (decreased systemic blood pressure). Furthermore, the mechanism lacks interaction with the nociceptive (pain) signaling pathway, confirming the absence of intrinsic analgesic properties.

How to Use Relaquine

Relaquine (Acepromazine maleate) is used according to clinical guidelines, defining its administration as a parenteral injection for animals. The medicine is formulated as an injectable solution for use by or on the order of a licensed veterinarian.

---

Official Administration Routes and Dosage

Commonly utilized routes of administration for the injectable solution include:

Route of Administration	Dosing Principle
Intravenously (IV)	Dosage must be individualized based on the patient and the required level of tranquilization.
Intramuscularly (IM)	The required dose in milligrams per pound of body weight decreases as the animal's overall weight increases.
Subcutaneously (SC)	Specific dosage instructions apply for dogs, cats, and horses, with distinct mg/lb or mg/100 lb ranges.

---

Administration Timing and Special Considerations

Dosing Frequency: Relaquine is typically administered as a single dose for procedures and is classified for as-needed (procedural) use. The dosage may be repeated only as determined necessary by the supervising professional.

Procedural Constraints: When administered intravenously, the dose must be injected slowly. A waiting period of at least 15 minutes post-IV injection is required to allow the full tranquilizing effect to be reached.

Population Adjustments: The dose should be lower for large breeds and animals with known sensitivities, such as Boxers and Greyhounds, to ensure administration adheres to the lowest possible effective quantity. For dogs with the MDR1/ABCB1-1Delta mutation, a significant dose reduction is indicated due to risk of prolonged effect.

Relaquine: Recent Clinical Evidence

The research supporting the active ingredient in Relaquine, Acepromazine maleate, consists primarily of clinical efficacy trials, comparative studies, and field observations submitted to regulatory bodies. These investigations focus on the short-term patterns observed during the substance's use in specific veterinary contexts.

---

Evidence for Tranquilization and Sedation for Restraint

Research has explored the use of this substance in the context of sedation and facilitating physical restraint during procedures. Studies involved healthy populations of horses, dogs, and cats. Researchers monitored patterns related to the required degree of restraint needed, often utilizing subjective scoring systems. Follow-up durations were typically limited to the immediate few hours after administration. Findings describe patterns observed in the studies but do not fully characterize the duration of observed patterns beyond this short, procedural window.

---

Evidence for Use as a Pre-Anesthetic Sedative

Relaquine has been evaluated in comparative studies examining its administration prior to general anesthesia. Trials monitored physiological variables, functional measures, and the dosage of subsequent anesthetic agents. Since this substance was frequently studied in combination with other agents (e.g., opioids), interpretation of study patterns with the substance alone is more complex. Follow-up durations were strictly acute, and limited information is available for post-operative outcomes.

---

Evidence for Relief of Acute Behavioral and Motion Sickness Symptoms

The evidence base supporting the use of this substance in the context of acute situational excitement and motion sickness (nausea and vomiting) includes clinical efficacy trials and older case reports. Studies monitored outcomes such as the frequency of vomiting episodes observed during acute transport. The evidence base supporting this antiemetic use includes data derived from historical regulatory reviews, with a relative scarcity of modern, highly controlled randomized trials specifically focused on this endpoint.

---

Long-Term Studies, Specific Populations, and Uncertainty

The majority of studies focused on short-term patterns observed during the study period, reflecting its primary use in acute settings. Consequently, there is limited information for outcomes related to the maintenance or durability of sedative patterns over extended periods. Data for pediatric or geriatric subjects and those with pre-existing conditions are often insufficient, as such populations were frequently excluded from initial efficacy trials. The isolated pattern of the substance is not always clear in combination protocols, which can contribute to uncertainty.

Key Studies & References

1. Acepromazine Maleate Injection (Veterinary) Official Label and Effectiveness Summary
2. Acepromazine: A Neuroleptic Agent in Veterinary Medicine (Mechanism and Clinical Use)
3. Acepromazine: Clinical Pharmacology and Use in Dogs, Cats, and Horses (General Review/Contraindications)

Common questions about Relaquine (FAQ)

Q: How long does it take for Relaquine to start working?

Official regulatory documents indicate that when the injectable solution is administered intravenously (IV), a period of at least 15 minutes is required to ensure the full tranquilizing effect has been reached. The exact time for the start of effects is not explicitly stated, and the full onset of effect may vary by administration route.

Q: Are there any food interactions to consider?

Regulatory warnings mention a specific interaction between the active ingredient and certain oral products. Official information states that antacids may decrease the absorption of the active ingredient when it is used in an oral formulation. Guidance on food interactions is specifically noted for oral formulations of the active ingredient.

Q: Can Relaquine be used for long-term behavior modification?

Relaquine is typically administered as a single, acute dose for specific procedures. The official evidence base primarily reflects its use in these acute settings. Because of this, limited information is available concerning the maintenance or durability of sedative patterns over extended periods.

Q: What is the mechanism of action of Relaquine?

According to the official product information, Relaquine works by acting on the central nervous system (CNS) and the peripheral nervous system. It blocks specific D2 dopamine receptors in the brain, which causes marked CNS depression. It also acts peripherally by blocking Alpha1 adrenergic receptors, which relaxes blood vessels and can cause a reduction in systemic blood pressure.

Q: Is Acepromazine available in a generic version?

The active ingredient in Relaquine, Acepromazine maleate, is a substance that is available as a generic product in various formulations. This generic substance is used in veterinary medicine.

Q: What are the main signs of an overdose?

The official product documentation does not provide a comprehensive list of overdose symptoms. However, regulatory warnings include a caution against using Epinephrine to treat acute hypotension that results from an overdose, which implies that a severe and sudden drop in systemic blood pressure is a primary concern in that scenario.

Q: What are the long-term side effects to monitor for?

Official documentation notes that some adverse reactions have been observed to vary with the duration of use. Specifically, the risk of Peripheral Neuropathy, a disorder affecting nerves outside the brain and spinal cord, is documented to increase with long-term, continuous use. Gastrointestinal symptoms, such as nausea and diarrhea, are typically noted as more common during the first two weeks of treatment.

How to Store and Dispose of Relaquine: Official Requirements

Official regulatory information details specific requirements for the storage, stability, and disposal of Relaquine (Oral Gel for Horses).

Area	Requirement Summary
Storage Conditions	Store below 25 C. The product must be protected from light and must not be frozen.
Child Safety	Keep out of the sight and reach of children is a mandatory instruction.
Stability After Opening	Once the syringe/bottle is first opened, the product has a limited shelf life (e.g., 28 or 90 days), after which any unused portion must be discarded.
Handling & Packaging	The product should be kept in the original carton and stored in a dry place, replacing the cap after use.
Disposal	Any unused or expired Relaquine and associated waste materials must be disposed of in accordance with local requirements for veterinary medicinal products.